X4 Pharmaceuticals, Inc. — Form 8-K Summary
Event date: October 7, 2026. This current report announces a new secured term-loan facility and repayment of the company’s prior Hercules debt. It does not report quarterly operating results.
Financing and liquidity
- X4 and its wholly owned subsidiary entered into a loan agreement providing for up to $150.0 million: $80.0 million funded at closing and up to $70.0 million in additional loans, subject to borrower request, agent review, and lender discretion.
- A portion of the initial proceeds repaid the Hercules facility in full. The approximately $78.7 million payoff included $75.0 million principal, accrued interest, end-of-term and prepayment charges, and related fees and expenses. The filing does not specify the remaining proceeds after repayment and fees.
- The new loans bear cash interest at the greater of 8.55% or the Wall Street Journal prime rate plus 1.55%, plus 1.0% annual paid-in-kind interest. Cash interest is payable monthly.
- Interest-only payments run through October 1, 2029; the period may extend to maturity if specified conditions are met, including first U.S. commercial sales of mavorixafor in moderate to severe chronic neutropenia. Principal and interest are then payable in equal monthly installments. Maturity is October 1, 2030.
- The debt is secured by substantially all borrower assets other than intellectual property. Loans cannot be reborrowed once repaid. Full prepayment is permitted subject to fees and notice requirements; a final payment fee is also due at repayment.
- The report provides no revenue, profit, cash-flow, margin, or unrestricted-cash balance figures.
Changes, terms, and risks
- The Hercules loan agreement and related loan documents were terminated after repayment; related liens and security interests were released. Previously issued Hercules warrants remain outstanding.
- Beginning October 1, 2027, while the company’s market capitalization is below $800.0 million, it must maintain unrestricted cash and cash equivalents of at least 75% of total outstanding loan obligations. The threshold falls to 40% after specified conditions are met.
- Beginning April 1, 2029, the borrowers must achieve trailing three-month net product revenue of at least 50% of the amount in board-approved projections.
- The agreement includes customary affirmative and negative covenants and events of default, including payment defaults, insolvency, and a material adverse effect.
- Lenders may convert up to $15.0 million of outstanding principal into common stock at $3.2341 per share, subject to adjustment and beneficial-ownership limits. Any shares would be issued under a registration exemption.
Investor verification points
- Review the full loan agreement when filed with the company’s Form 10-Q for the quarter ended September 30, 2026, especially fees, conditions for the additional $70.0 million, covenant definitions, and default provisions.
- Verify the net cash available after the Hercules payoff and other transaction costs, and the company’s liquidity relative to future cash-maintenance requirements.
- Monitor progress toward the mavorixafor commercial-sales condition and the 2029 product-revenue covenant.
- Assess potential dilution if lenders exercise conversion rights and confirm the terms of the outstanding Hercules warrants.